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ABSTRACT
Jun/Fos and Jun/BATF heterodimers are capable of binding the TRE site to regulate gene 
transcription, which in turn amongst other functions, could be involved in the regulation of 
inflammation. Studies have shown that in contrast to Jun/Fos, the Jun/BATF heterodimers result 
in a reduced transcriptional activity and thus inhibit the expression of AP-1 target genes.
The inflammatory response is composed of a vast array of mediators, including cytokines such as 
IL6 and IL10. The balance between pro-inflammatory and anti-inflammatory mediators, in part, 
determines whether the inflammatory response persists or is resolved. Macrophages are a key 
cell type involved in the inflammatory response.
The goal of this research was to determine the expression of BATF in comparison to Fos 
expression when M1 cells were stimulated with the known inflammatory triggers, IL6, IL10 and 
LPS. Although M1 cells do not express c-Fos, they do express Fra-1, which is also a member of 
the Fos family.
Stimulation of M1 cells with IL6, IL10 and LPS resulted in co-expression of BATF and 
Fra-1 as a result of stimulation with each inflammatory trigger. Further studies will be required to 
measure transcription factor binding to an AP-1 consensus DNA sequence. This would give more 
conclusive evidence as to which of the two dimers Jun/BATF or Jun/Fos is actually binding and 
thus giving rise to the control of the TRE site following the stimulations. This would also show 
whether the transcription factor that was predominantly expressed produced its effect through the 
TRE site or whether on the contrary, BATF and Fra-1 were coexpressed and had different 
promoter targets.
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CHAPTER 1 
LITERATURE REVIEW
OVERVIEW OF THE ROLE OF MACROPHAGES IN INFLAMMATION:
Macrophages are continually responding to injury, infection, trauma and many other 
insults from the environment (1, 2, 3). The ability to respond to these stimuli makes them key 
players in the maintenance of tissue homeostasis. If macrophages are unable to reestablish 
tissue homeostasis alone, they mobilize and orchestrate other cellular systems to restore normal 
function. The inflammatory response is an example of a reaction brought about by the 
macrophages in response to environmental changes (1, 3).
Inflammation is a vital response and an integral function of the body’s immune system. 
This response, which includes both localized and systemic effects, consists of altered patterns of 
blood flow, an influx of phagocytic and other immune cells, production of a series of tissue 
mediators, removal of foreign antigens and healing of the damaged tissue (4, 5, 6).
Macrophages have a class of receptors known as toll-like receptors (TLRs), which 
recognize a given class of molecules that are unique to microorganisms (5, 7, 8, 9). The 
recognition of these bacterial molecules by the TLRs is known as pattern recognition and it is a 
part of innate immunity. Through these TLRs the macrophage is able to detect the presence of 
bacteria. For example TLR4 recognizes the presence of lipopolysaccharide (LPS), the major 
glycolipid on the outer membrane of Gram negative bacteria. Engagement of TLR4 elicits 
activation of the TLR4 signaling pathway and results in the production of a series of inflammatory 
mediators in the macrophages such as lysosomal enzymes, cytokines, reactive oxygen species, 
prostaglandins and nitric oxide. The lysosomal enzymes, activated oxygen species and nitric 
oxide all function in killing of the microbe during phagocytosis (3). Once phagocytosis has taken 
place, the antigen is then processed and presented. Macrophages present specific bacterial 
antigens to effector T cells on site to carry on adaptive immunity.(5, 8).
The inflammatory mediators produced by macrophages are important, amongst other 
functions, for the recruitment of other cell types such as neutrophils to help with the response (5, 
6,10). During the inflammatory response, this integration of innate and adaptive immunity results 
in the elimination of the invading organism.
INFLAMMATION:
The term inflammation largely describes the vascular events that cause the ‘cardinal 
signs’ of inflammation. These signs are: Redness due to vasodilation that increases blood flow 
to the site of inflammation; swelling due to changes in vascular permeability that allows leakage 
of fluid into the tissues; heat because increased blood flow to the site of infection increases local 
temperature; pain due to mediators produced at the site of inflammation that sensitize nerve 
endings (3,4,5,6). A variety of tissue mediators are produced during the inflammatory response 
and these function in perpetuating this response (2). These mediators are released by cells 
damaged from tissue injury, produced by the invading microorganisms, or are products of the 
white blood cells that participate in the inflammatory response. The mediators that cause the 
vasodilation are prostaglandins and nitric oxide. Increase in vascular permeability is brought 
about by vasoactive amines, bradykinin, leukotrienes C4, D4 and E4 and platelet-activating 
factor acting on the endothelial cells. Chemotaxis and leukocyte activation are a result of 
bacterial products, leukotriene B4, C5a, and cytokines such as IL-1, IL-6, TNF-a and 
prostaglandins acting systemically to induce fever during the response. The pain is brought 
about by prostaglandins and bradykinin sensitizing nerve endings. In addition to the tissue 
damage from the microbe itself, the mediators also cause tissue damage when released 
prematurely by overactive phagocytic cells (4, 5, 6).
Acute inflammation is short term, usually lasting a couple of hours to a few days, 
depending on the degree of insult. It is beneficial to the body in the sense that during acute 
inflammation, cells are recruited to deal with an infection or a foreign body. Once the infection or 
foreign body is cleared, the inflammatory response subsides. However, inflammation may act as 
a double-edged sword because an excessive and prolonged response can cause tissue 
damage, contributing to the pathogenesis of many disease states. This prolonged response, 
usually lasting weeks to months to years, is chronic inflammation that occurs when the acute 
response cannot be resolved. This is either because of persistence of the injurious agent or 
because of interference in the normal process of healing. Changes that occur during chronic 
inflammation often lead to more harm than good. Macrophages are central to the inflammatory
response because they secrete cytokines that are crucial for triggering the inflammatory 
response and they also respond to cytokines via receptors on their surfaces (2, 3, 4). These 
receptors make them capable of responding to many different cytokines and thus control a 
myriad of responses in the body (Table 1, p31).
Cytokines are a class of proteins that act as intercellular signals to integrate and control 
those cells involved in immune responses. Cytokines are produced principally by activated 
macrophages and leukocytes. They can have autocrine, paracrine or endocrine effects. They 
may also act on multiple target cell types (pleiotropy). Cytokines have no inherent activity; their 
biological actions are dependent on the expression of their cognate receptors on the target cells 
(5, 6, 10). Cytokine receptors are expressed on many different cell types and these receptors are 
structurally diverse.
THE MACROPHAGE RESPONSE:
Macrophage surface receptors regulate different activities such as inflammation because
the type of response obtained from their activation is dependent on the cytokine that bound to 
the cytokine receptor on the macrophage and the corresponding signaling pathway that was 
triggered (1, 5, 10). The type of response obtained is dependent on the cytokine that engaged 
the receptor in the first place. Activation of the macrophages by the binding of the different 
cytokines results in the transcription of genes for the production of various secretory products 
including enzymes, complement components, coagulation factors, cytokines and other mediators 
(1 ,10,11) (Table 2).
The cytokines secreted by macrophages recruit and activate other cells to carry on the 
inflammation. The macrophage response therefore must be under strict control in order to avoid 
the pathological effects of many chronic inflammatory disease states. (5).
The inflammatory response is composed of an elaborate cascade of inflammatory 
mediators. As with other tissue homeostatic responses, the immune response has built in 
mechanisms to counteract the inflammatory response. This ensures that the response is 
sufficient to clear the insult but does not cause excessive harm to the body. When macrophages 
first respond to an insult, the response produces inflammation and as the insult is cleared, the
healing process begins. In contrast, the persistence of an insult causes continued tissue 
destruction, inflammation, repair and healing. Both pro-inflammatory and anti-inflammatory 
mediators are produced and the inflammatory response persists and intensifies (i.e. becomes 
chronic), instead of being limited and leading to resolution (1, 2, 3, 12).
CHRONIC INFLAMMATION:
Chronic inflammation usually occurs as a progression from acute inflammation or after 
repeated episodes of acute inflammation. Microorganisms such as Mycobacteria tuberculosis (M. 
tuberculosis), Actinomycetes, and numerous fungi including Cryptococcus neoformans, protozoa 
and metazoal parasites induce chronic inflammation by possessing mechanisms for resisting or 
evading the immune response. Such organisms are either able to avoid phagocytosis or survive 
within phagocytic cells. M. tuberculosis is able to survive within the macrophage phagosome after 
phagocytosis and thus presents a continuous activation of the macrophage, resulting in chronic 
inflammation (1, 13).
When bacteria are phagocytosed, they are taken up into the endosomal system of the 
cell where two processes should take place. Normally, the bacteria are first killed and then the 
bacterial peptides are presented on Major Histocompatibility Complex II (MHO II) proteins in order 
to stimulate a humoral response to the bacteria (5). Macrophages present these peptides to T 
helper cells that become primed after recognition of the processed antigen. However it has been 
shown that M. tuberculosis inhibits MHO II expression on infected phagocytes. This disrupts the 
sequence of events of antigen presentation and thus these organisms survive. It has also been 
shown that M. tuberculosis inhibits phagosome-lysosome fusion. Mycobacteria may act from 
within the macrophage phagosomes to prevent phagolysosome formation and thus avoid the 
lysosomal hydrolases. The infected macrophage (normally in the lung alveoli) also produces 
chemokines that attract monocytes and neutrophils. However none of these cells are able to 
effectively kill the M. tuberculosis due to its intracellular location. The mycobacteria are not killed 
but instead persist, resulting in the continual macrophage activation. Persistence of the causative 
stimulus to inflammation in the tissue leads to the classic tuberculosis granuloma. These are 
tumor-like masses that contain many activated macrophages, T helper cells and multinucleated
giant cells formed by the fusion of macrophages. This "contained" form of tuberculosis is 
characterized by low numbers of infecting mycobacteria but high levels of inflammation (13, 14).
Chronic inflammation also occurs in a number of autoimmune diseases such as in 
systemic lupus erythematosis (SLE) and rheumatoid arthritis. In these conditions, the disease 
process is initiated by an insult that damages tissues and is then maintained because of an 
abnormality in the regulation of the body's immune response to its own tissues. This results in a 
self-perpetuating immune reaction because the antigens causing the response are self proteins 
and therefore persist (5). The etiology of rheumatoid arthritis is unknown but the pathogenesis of 
rheumatoid arthritis is based on pathophysiological and experimental evidence that shows an 
exogenous or self-antigen enters the synovium and is presented to CD4+ T cells. A cascade of 
events follow, that result in a highly activated inflammatory environment. A wide range of 
inflammatory mediators, including cytokines and their inhibitors, are produced in abundance. The 
synovial membrane overgrows and begins to invade the articular cartilage as large numbers of 
macrophages, as well as other cartilage cells at the synovium-cartilage interface secrete matrix- 
degrading proteolytic enzymes. The macrophages also secrete inflammatory cytokines. These 
interlinking events result in the synovial inflammation. The degree of joint damage that follows 
depends on the intensity of the inflammation (5,15).
Prolonged exposure to exogenous non-degradable toxic agents such as particulate silica 
can also induce a chronic inflammatory response in the lungs, leading to silicosis. In the normal 
lung, defense functions are mediated by epithelial cells of the airways and alveolar regions, 
resident alveolar macrophages and numerous proteins in the extracellular spaces. The epithelial 
cells provide a mechanical barrier that retards the entry of foreign substances. Mucous entraps 
the exogenous substances. The cilia on the epithelial cells help propel the exogenous substances 
out of the body (3, 4). Resident lung macrophage provide lung defense by phagocytosis of foreign 
particles and secretion of cytokines (16). In the presence of persistent exogenous substances, 
infiltration of phagocytes, specific immunologic mechanisms, such as antibody production by B 
lymphocytes and cellular cytotoxic actions by T-lymphocytes augment the primary defense 
functions. Inflammatory cells recruited into the lungs tend to produce indiscriminate injury to
resident lung cells and tissues by non-selective release of proteases, oxygen free radicals, and 
other cytotoxic agents. This non-selective release of mediators is due to the premature release of 
proteases from overactive macrophage lysosomes. This results in a chronic inflammatory state 
as the exogenous substance such as silica, which is non- degradable, cannot be readily cleared. 
In these conditions, accumulation and activation of macrophages is the hallmark of chronic 
inflammation (17).
Apart from chronic inflammation in itself being a problem, as shown in the previous 
examples, chronic inflammation can give rise to other problems such as the development of 
cancer. A substantial body of evidence supports the suggestion that chronic inflammation can 
predispose an individual to cancer (18, 19, 20), as demonstrated by the association between 
chronic inflammatory bowel diseases and the increased risk of colon carcinoma. A study by 
Bernstein et al. examined the incidence of colon cancer among persons with inflammatory bowel 
disease (IBD) compared with those of a non-IBD population. The longer the inflammation 
persisted, the higher the risk of dysplasia, which was then followed by carcinogenesis. (21). The 
fact that chronic inflammation impacts crucial cellular processes such as proliferation, adhesion, 
apoptosis and transformation highlights its pivotal role in the pathogenesis of malignancy.
These examples give an indication of the role played by chronic inflammation in the 
pathogenesis of different diseases. An understanding of the regulation of the inflammatory 
response will contribute greatly towards progress in the management and treatment of these 
diseases.
TRANSCRIPTIONAL REGULATION OF THE INFLAMMATORY RESPONSE:
Evidence suggests that the inflammatory response initiated by the pro-inflammatory 
cytokines produced by macrophages is counterbalanced by anti-inflammatory cytokines that turn 
off the process when the pathogen or primary cause is eliminated (6,12). Because macrophages 
are key amplifiers of the inflammatory response, it is important that these cells are tightly 
regulated. The macrophage response to changes in the environment is largely controlled by the 
regulation of gene expression. Transcription factors are regulatory proteins capable of binding 
directly to DNA sequences and mediating the binding of RNA polymerase for the initiation of
transcription; they can either stimulate or repress transcription of a gene. These transcription 
factors therefore play a role in converting extra-cellular signals into changes in the expression of 
specific genes and thereby regulate complex biological processes (11). Furthermore, 
transcriptional activity represents an integration of all the signals coming from the macrophage’s 
environment to generate an appropriate response.
When a macrophage is activated through the binding of a cytokine to its receptor, a 
series of intracellular events leads to the transcriptional activation of specific genes. This means 
that transcription factors bind to the regulatory region (promoter) of a gene and this allows the 
gene product to be expressed. Transcriptional regulation of eukaryotic genes often requires the 
cooperative or antagonistic action of several proteins. These proteins translocate into the nucleus 
and function either individually or cooperatively in regulating the expression of target genes. The 
type of response obtained from the activation is dependent upon which cytokine receptors are 
engaged, other signals acting on the macrophage and the resulting combination of transcription 
factors activated in the nucleus of the macrophage (11). Likewise, the resolution of inflammation 
requires specific signaling events (1). Inflammation can be turned off in a number of ways such as 
by the degradation of transcription factors, inactivation of the transcription factors by processes 
such as dephosphorylation, or modulation of proteins required for transcription factor regulation 
(11).
Most advances in the understanding of the contribution of transcription factors in 
macrophages have focused on the induction of the inflammatory response rather than its 
resolution. An example of a well-studied transcription factor that is activated during the 
inflammatory response is the transcription factor activator protein 1 (AP-1). It was initially 
described as a heterodimer of c-Jun and c-Fos that binds to the 5 -TGAGTCA-3' motif known as 
the TPA (PMA)-responsive element (TRE) (22,23). However, current views suggest that AP-1 
represents a family of distinct homodimers or heterodimers composed of various members of the 
Fos, Jun and ATF basic leucine zipper family (24, 25) (see figure 1 ).
Members of the leucine zipper family include c-Jun, JunB, JunD, c-Fos, Fos-B, Fra-1, 
Fra-2, ATF-2, ATF-a and ATF-3 (24, 26). The leucine zipper motif is an alpha helix of 30-40
amino acid residues that contains a leucine every seven amino acids, positioned so that they 
align on the same side of the helix. Two helices dimerize so that the leucines of one helix align 
with the other helix through hydrophobic interactions to form a coiled coil. The portion of the dimer 
known as the DNA binding domain (DBD), adjacent to the zipper, interacts with the DNA through 
basic amino acid residues (arginine and lysine) that bind to the negatively charged phosphate 
groups of the DNA (11, 24, 26, 27).
Several homologues of c-Jun (JunB and JunD) and c-Fos (Fos-B, Fra1 and Fra2) have 
also been shown to form heterodimers. Fos/Jun heterodimers have a higher affinity for DNA 
binding than Jun homodimers. Enhanced DNA binding activity of the Fos/Jun heterodimer 
compared to Jun homodimers can be explained by the rate of association and dissociation from 
the TRE and/or by the stability of protein molecules in the dimeric state. Jun homodimer 
dissociates very rapidly from the DNA while the off-rate of the Fos/Jun heterodimer is 
considerably slower, reflecting its higher affinity (27, 28). In addition, members of the activating 
transcription factor (ATF) family, such as BATF, ATF-2, ATF-3 and ATF-4, can interact with 
members of the Fos and Jun family of proteins. Whereas Jun and some ATF proteins form stable 
homodimers as well as heterodimers, c-Fos is incapable of binding DNA as a homodimer. 
Therefore c-Fos exhibits no biological activity as a homodimer. BATF forms heterodimers with 
Jun that bind to consensus ATF/AP-1 DNA sites (29). BATF does not form homodimers, nor does 
it form heterodimers with Fos or with other bZIP proteins (26).
AP-1 is activated in response to a diverse range of stimuli. Many genes have AP-1 sites 
in their promoters. Thus AP-1 is involved in the regulation of a large number of genes. Although 
the core sequences of the AP-1 binding sites show a high degree of homology, the variation in 
these binding sites suggests that different AP-1 complexes may bind with varying affinities and 
differentially affect transcription of specific target genes. To understand the biological functions of 
AP-1, it is important to elucidate the roles that individual basic leucine zipper proteins play in the 
cell as part of the AP-1 complexes. For example, the Fos/ Jun heterodimers bind with high affinity 
to the sequence motif 5'-TGAGTCA-3'. A c-Jun/ATF2 heterodimer shows low binding activity to 
the same motif, however, this heterodimer binds with high affinity to the sequence 5 -
TTACCTCA-3' found in the c-Jun promoter. Thus different DNA sequence elements are 
preferentially recognized depending on the composition of the AP-1 dimer.
Basic leucine zipper family proteins are common regulators of gene expression in a 
variety of tissues and cell types (24, 26, 27, 28). A bZip protein found mostly in hematopoietic 
tissue is BATF. We were particularly interested in this protein because it appears to be involved in 
the negative regulation of the responses mediated by Fos/Jun. The first isolation of BATF was 
from a cDNA library prepared from human B cells which had been infected with the Epstein-Barr 
virus (EBV, 30, 31 ). Analysis of other human tissues and cell lines revealed expression of the 
940-base BATF mRNA predominantly in tissues of hematopoietic origin, (30) with constitutive 
expression in T lymphocytes and inducible expression demonstrated in B lymphocytes from 
peripheral blood (32). Flowever the highest level of BATF was detected in an EBV-positive human 
B-cell line known as Raji, which is a cell line derived from Burkitt’s lymphoma. EBV-negative 
human B cells from peripheral blood do not express BATF until infected with biologically active 
EBV. Studies demonstrate that within 24 hours of infecting human B cells with biologically active 
EBV, BATF mRNA is induced 25-fold, suggesting that the induction of BATF mRNA and protein is 
an early cellular response to the virus (30). It is also known that EBV and HTLV-1, human viruses 
associated with long periods of latency, upregulate the expression of BATF in cells. It is possible 
that these viruses induce BATF in the cell to regulate gene expression required for latency (30, 
32).
BATF is able to form dimers with members of the Jun transcription factor family to bind to 
AP-1 promoter sites in the DNA to carry out its regulatory activity. Studies have also shown that 
the BATF/Jun heterodimers result in a decreased transcriptional activity of the target gene, thus 
inhibiting the expression of the AP-1-regulated protein (32, 33). This is in contrast to Fos/Jun 
heterodimers. Thus Fos/Jun promotes the transcription of certain genes and BATF/Jun prevents 
transcription of those same genes (26, 32) (Figure 2).
This suggests that the major cellular function of BATF is as a negative regulator of AP-1 
mediated transcriptional events. This is of particular interest to us because it could suggest a 
possible role for BATF during inflammation, especially given that its expression is specific to
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hematopoietic tissue. Fos has been shown to be a key transcription factor involved in the 
inflammatory response, and the question becomes “Is BATF a key transcription factor involved in 
the resolution of inflammation?” The goal of this research was to explore the timeline of 
expression of BATF and Fos in response to LPS and to the cytokines IL-10 and IL-6. As 
mentioned, LPS is the major glycolipid on the outer membrane of gram-negative bacteria. 
Activation of macrophages by LPS is known to result in production of cytokines necessary for the 
inflammatory response via the MAP kinase and NF-kB pathways (5, 40). Both pathways lead to 
upregulation of AP-1 mediated responses. IL-10 has been shown to be a major anti-inflammatory 
cytokine. Engagement of IL-10 or IL-6 receptors on macrophages activates the STAT-3 pathway 
and STAT-3 has been shown to induce BATF expression. (5, 12, 35, 36, 37). IL-6 also activates 
the MAP kinase pathway via an SHP-2 domain. SHP-2 transmits signals to the Ras pathway 
through Grb2/Sos and/or Gab1/Gab2, resulting in the activation of ERK MAP kinases. Below is a 
discussion of the signaling pathways of the stimuli that are of relevance to this research.
TLR-4 PATHWAY:
The TLR-4 pathway is relevant to this research because cells respond to the presence of 
LPS through this pathway. LPS is a known stimulant of inflammation. (3, 4, 5) Toll-like receptors 
(TLRs) are the principal signaling molecules through which the innate immune system senses 
infection and the endpoint of this signaling pathway is the production of cytokines. TLRs are 
therefore an important link between the mammalian host and the microbe by making the host 
aware that pathogens are present. TLRs are classified into ten categories based on the types of 
microbial products they recognize (38). Each TLR recognizes a unique set of molecules produced 
by microbes, known as pathogen-associated molecular patterns (PAMPs). Macrophages respond 
to the presence of LPS via TLR4 by producing pro-inflammatory cytokines (i.e. IL-1, TNF-a and 
IL-6), bioactive lipids (such as prostaglandins) and reactive oxygen species. LPS is therefore pro- 
inflammatory in nature. Once TLR4 is engaged, the LPS/TLR4 complex undergoes a 
conformational change that is sensed in the cytoplasmic compartment (see figure 3). This 
mediates the recruitment of MyDSB to the Toll-IL-1 resistance (TIR) domain of the LPS/TLR4
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complex (40). The recruitment of MyD88 to the proximal TIR allows for the interaction with the IL- 
1 R-associated kinase (IRAK) family members. IRAK is then auto-phosphorylated and ieaves the 
receptor complex to interact with TNF receptor associated factor (TRAF)-6. The subsequent 
activation of (TRAF)-6 results in two signaling pathways becoming activated i.e. NF-kB pathway 
and the MAP kinase pathway. The MAP kinase pathway, also known as the extracellular-signal 
regulated protein kinases (ERKs) is a signaling pathway that responds to extracelluiar signals 
such as cytokines, growth factors and stress which terminate in a three MAP kinase enzyme 
cascade. In this cascade, each enzyme phosphorylates the next, thereby activating it (7, 38, 40, 
41,42).
In the LPS induced MAP kinase pathway, (MEKK-1) MAPK kinase kinase 1 is activated 
by TRAF-6 via the protein adaptor molecule ECSIT. MEKK-1 in turn activates MEKK-4, which 
results in the phosphorylation and activation of Jun kinase (JNK). JNK then activates the 
transcription factor AP-1 via phosphorylation of Jun. 12-0-tetradecanoyl phorbol-13-acetate 
(TPA) is known to upregulate both Fos and Jun through the MAP kinase pathway, and this could 
possibly mean that LPS acts on Fos and Jun in the same manner because it uses the same 
pathway as TPA (38).
Recruitment of the adapter TRAF6 also leads to the activation of the inhibitory kappa B 
(IkB) kinase (IKK) complex. The kinase then phosphoryiates IkB. Phosphorylation of IkB results in 
its release from the NFkB dimer. N FkB then translocates into the nucleus, where it activates 
genes encoding inflammatory proteins such as IL6 (41, 42). There is no known direct effect of 
NFkB on Fos or BATF. However, it has been shown that at the transcription level NFkB interacts 
with Fos/Jun synergistically, leading to greater inflammation than would be present if either NFkB 
or Fos/Jun were activated alone (42).
IL-6 AND IL10 PATHWAYS:
IL-6 and IL-10 were relevant to this research because the presence of these cytokines 
results in the activation of STAT-3. STAT-3 activation is also known to result in an increase in
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BATF (34). Studies by Gao et al. (43) show that in animal models of sepsis, STAT-3 is the most 
important mediator of anti-inflammatory signals in macrophages. In fact the loss of STAT-3 in 
hematopoietic-specific knockout mice resulted in progressive inflammatory bowel disease (43). 
Given the above information, we decided to explore what effect stimulation of M1 cells with 
either IL-10 or IL-6 would have on the levels of expression of BATF and Fos.
INTERLEUKIN-6
Macrophages express IL-6 receptors on their cell membranes (1, 5) and consequently 
are capable of responding to the cytokine IL-6. The IL-6 receptor belongs to the Class I cytokine 
receptor family, also known as the hematopoietin receptor family. In addition to being a member 
of the class I family, the IL-6 receptor belongs in the IL-6 receptor subfamily. IL-6, IL-11, 
Leukemia Inhibitory Factor (LIF), Oncostatin M (GSM) and ciliary neurotrophic factor (CNTF) 
receptors belong to this subfamily (5).
This subfamily is characterized by receptors that have glycoprotein 130 (gp130) as a 
common signal transducing subunit. The IL-6 receptor is composed of two different subunits, an 
alpha subunit (IL-6R») and gp130. The alpha subunit provides ligand specificity and the 
glycoprotein is the signal transducing subunit (5, 44, 45). IL-6 uses tyrosine kinases of the JAK 
family and transcription factors of the STAT family as major mediators of signal transduction. 
The signal is initiated when IL-6 interacts with two independent ligand binding alpha subunits. 
Once IL-6 engages these subunits, a series of intracellular events are initiated (see figure 4).
Receptor engagement induces dimerization of gp130 with another gp130 subunit 
(homodimerization) and signaling is triggered. Homodimerization of gp130 leads to gp130- 
associated Janus kinase (JAK) activation i.e. JAK1, JAK2, or tyrosine kinase 2 (Tyk2). Activation 
of these kinases results in the phosphorylation of the cytoplasmic tail of gp130. Several 
phosphotyrosine residues of gp130 are docking sites for STAT factors (mainly STAT-1 and 
STAT-3) via their SH2 domains. SH2 domains are responsible for the binding of the STATs to 
the tyrosine-phoshorylated receptor motifs and also for homodimerization or heterodimerization 
with other tyrosine phosphorylated STATs. Activated JAK kinases phosphorylate and activate
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STAT transcription factors, particularly STAT-3 and SHP2 (Src Homology-2 Domain-containing 
Tyrosine Phosphatase). Phosphorylated STATs then form dimers and translocate into the 
nucleus where they regulate transcription of STAT target genes by binding to Interferon 
regulatory factor response element (IRE) motifs in the associated promoter. SHP2 is a tyrosine 
phosphatase that contains two SH2 domains. Upon binding to a phosphotyrosine motif, the 
phosphatase becomes activated and might be involved in dephosphorylation of Jaks and their 
associated receptors. This would be important for inhibiting the continual activation of the STATs 
and thus would be Important in down regulating the response they produce. Moreover, SHP2 
acts as an adapter protein that links gp130 to the mitogen-activated protein kinase (MAPK) 
pathway, which is also activated upon IL-6 stimulation (44, 45, 46).
The cytokine IL-6 is produced by macrophages and endothelial cells (5). IL-6 Is a key 
mediator of inflammation because it is involved in inducing the systemic effects of inflammation, 
collectively known as the acute phase reaction. IL-6 stimulates the hepatic synthesis of acute 
phase proteins; it influences adaptive immunity (proliferation and antibody secretion by the B cell 
lineage); it stimulates T cell proliferation and differentiation into cytotoxic T effector cells. In 
addition, IL-6 is pyrogenic, increases vascular permeability, and increases intracellular pH. IL-6 
also acts on the bone marrow stem cells, stimulating the monocyte precursor cells to proliferate 
(1), thus producing monocytes that can migrate into tissues to become macrophages when 
needed.
INTERLEUKIN-10
IL-10 is also important in macrophage function. Interleukin-10 (IL-10) activates a diverse 
array of functional responses in mononuclear phagocytes. It is secreted by macrophages and by 
activated T and B cells and serves to inhibit production of many pro-inflammatory cytokines such 
as IL-1, IL-6, IL-8, IL-12, GM-CSF, G-CSF, M-CSF, TNF, NF, MIP, MIP-2 and RANTES. IL-10 is 
therefore considered as the primary anti-inflammatory cytokine of the immune system because it 
inhibits the production of many other inflammatory mediators (1, 5, 35).
IL-10 synthesis usually occurs during the inflammatory response. If IL-10 is neutralized, 
the inflammatory condition usually exacerbates. IL-10 has therefore been suggested as a
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possible therapeutic cytokine for chronic inflammatory conditions such as in autoimmune 
diseases and septic shock. However, a study by Avdiushko et al. showed that macrophages from 
mice chronically infected with the LP-BM5 retrovirus, producing a chronic inflammatory condition, 
had reduced ability to respond to IL-10. They demonstrated IL-10 production was elevated and 
that the elevated expression of IL-10 was caused by the decrease in the responsiveness of 
macrophages to IL-10. This hypo-responsiveness was not caused by changes in the expression 
of the IL-10 receptor, suggesting regulation at the signaling level (37). This could have 
implications in using IL-10 as a therapeutic tool, because regardless of the amount of IL-10 given, 
hypo-responsiveness of IL-10 receptors during chronic inflammation would result in failure of IL-
10 to have anti-inflammatory effects or to reduce the pro-inflammatory cytokine effects.
Macrophages and monocytes express the IL-10 receptor, which is a member of the Class
11 cytokine receptor family, also known as IFN-receptor family. It is a tetramer consisting of two IL- 
10R1 polypeptide chains and two IL-10R2 chains. Both IL10-R1 and 1L10-R2 belong to the IFN- 
receptor family (5, 35). The IL-10R1 subunit is constitutively associated with JAK1 and is mainly 
involved in downstream signaling. Once the IL-10 receptor is engaged (see figure 5), IL-10R2 
acts as an accessory subunit that recruits the second kinase, tyrosine kinase 2 (Tyk2), to the 
receptor complex. Upon binding of IL-10 to the IL-1 OR subunits, the JAKs are activated by 
transphosphorylation. The activated JAKs then phosphorylate IL-10R1, creating docking sites for 
STAT transcription factors such as STAT-3. The intracellular part of the IL-10R1 contains two 
tyrosine motifs. Each of the single motifs is sufficient for full STAT-3 activation. STAT-3 becomes 
activated at the receptor through tyrosine phosphorylation by JAK, then forms dimers and 
subsequently translocates into the nucleus to induce STAT-3 target genes (35, 48, 49).
Even though IL-10 and IL-6 have similar signaling pathways, both have distinct systemic 
effects. The anti-inflammatory activity of IL-6 is relatively weaker than that of IL-10. This 
difference can be attributed to Suppressor of Cytokine Signaling-3 (S0CS3), the major feedback 
inhibitor of Jak/STAT signaling. IL-6 signal transduction is more sensitive to S0CS3 because 
SOCS3 is recruited to one of the five phosphorylated tyrosine residues in the signal transducer 
gp130 subunit. S0CS3 does not interact with phosphorylated tyrosine motifs of the IL-1 OR.
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Studies by Riley et al. have also demonstated a carboxyl-terminal 30-amino acid sequence in the 
intracellular domain of the IL-10 receptor not shared by IL-6 which is responsible for the 
additional anti-inflammarory function of IL-10 in addition to the STAT-3 pathway (48).
STAT-3 mediates cellular responses but the mechanisms underlying the diverse effects 
of this signaling molecule remain unknown. However BATF is likely to be a direct transcriptional 
target of STAT-3 because BATF transcription is dependent on the activation of the JAK/STAT-3 
signaling pathway (34). It has been shown that STAT-3 is a transcription factor mediating the anti­
inflammatory properties of IL-10 (43). However, we do not know if the anti-inflammatory effects 
are mediated through the induction of BATF expression.
OBJECTIVES AND GOAL:
We would propose very simply that the possible outcome in response to pathogens 
encountered by the macrophage would entail an inflammatory response followed by the 
resolution of inflammation. In this model, during the inflammatory response, we would expect Fos 
expression to be induced and its activity transiently increase to reach a threshold level for the 
inflammatory response. BATF expression would also be induced at the same time as Fos is 
induced, however BATF activity would slowly rise during this inflammatory phase. Most dimers 
formed during this phase will be Fos/Jun, as Fos competes with BATF for binding to Jun. In turn, 
gene expression controlled by AP-1 promoters will increase during the time that Fos expression is 
high.
As the pathogen is cleared, we would expect BATF to reach a threshold level for an anti­
inflammatory response above the expression of Fos. Fos expression would begin to decline. This 
then allows BATF to form dimers with Jun to take over and turn off gene expression. This would 
contribute to the resolution of inflammation. The outcome occuring at a given timepoint would 
depend on the type of signal conferred on the macrophage. Even though we expect coexpression 
of Fos and BATF, the dominant transcription factor would determine the type of response 
obtained. We would therefore expect known inflammatory triggers such as LPS to result in 
increased Fos production, whereas anti-inflammatory triggers such as IL-10 to result in increased 
BATF production (see figure 6).
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The goal of this research is to test the above mentioned simple model using the M1 cell 
line, to demonstrate that pro-inflammatory and anti- inflammatory stimuli have opposing effects on 
BATF and Fos expression. Since Fos/Jun and BATF/Jun can bind to the same motif in the 
promoter sequence (i.e. TGACTCA), we would predict that the response is determined by the 
dominant dimers formed. For example in the macrophage response to LPS, LPS is a pro- 
inflammatory mediator. Therefore we would expect Fos to dominate while LPS is present. BATF 
would then only dominate once Fos is degraded. Therefore we would predict that pro- 
inflammatory agents would cause a relative reduction in BATF in the cell. Thus we can map out a 
time course of Fos and BATF expression in M1 cells in response to different inflammatory 
mediators.
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CHAPTER 2
TRANSCRIPTIONAL REGULATION OF M1 CELLS IN 
RESPONSE TO IL-6, IL10 AND LPS
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CHAPTER 2.1 
INTRODUCTION
AP-1 consists of several distinct homodimers or heterodimers composed of various 
members of the Fos, Jun and AT F basic leucine zipper (bZip) family. Members of the leucine 
zipper family include c-Jun, JunB, JunD, c-Fos, Fos-B, Fra-1, Fra-2, ATF-2, ATF-a, BATF and 
ATF-3 (24, 26). “Leucine zipper” refers to the formation of an alpha helix that contains a leucine 
every seven amino acids. These leucines are positioned so that they align on the same side of 
the helix and facilitate the formation of dimers through hydrophobic interactions with other family 
members. Leucine zipper proteins also contain a basic region which has the binding site for DNA. 
In the case of AP-1 family members, dimerization must occur prior to DNA binding. Through 
dimerization, the DNA binding regions on the bZip proteins are positioned so as to be in the right 
conformation to bind the promoter site on the DNA (11, 24, 26, 27).
The bZip dimers were originally classified into four different sub-classes based on the 
promoter elements to which these bZip dimers would bind. The classes were AP-1, ATF/CREB, 
C/EBP and Maf. The AP-1 dimer subclass includes Jun/Jun, Fos/Jun and Jun/Fra dimers. These 
dimers bind to 5 -TGAGTCA-3', the TPA” (PMA)-responsive element (TRE). The ATF/CREB 
bZip members included CREB, ATF1, ATF2, ATFa, CREBP-2, ATF3, ATF4 and ATF6. The 
dimers of the ATF/CREB family bind to the cyclic AMP-responsive element (CRE) 5 -TGA CG 
TCA-3' (24,26,27,28). The only difference between the CRE and TRE site is an additional 
cytosine nucleotide in the CRE which is not in the TRE site (26). However, the distinction 
between AP-1 and ATF/CREB based on the promoter binding site did not apply in all instances 
because AP-1 dimers were sometimes capable of binding to the CRE site as well. AP-1 is now a 
more generic term for the dimers of the Fos, Jun and ATF basic leucine zipper family (26). The 
known dimers include Jun/Jun, Jun/Fra-1, BATF/Jun, c-Fos/c-Jun, JunB /c-Fos, JunB/FosB, c- 
Jun/ATF2 and ATF2/ATF2. Multiple bZip proteins can be expressed at the same time in the cell 
(26, 27). Expression of multiple bZip proteins at the same time implies that different AP-1 dimers 
are available at about the same time to bind to the DNA. The big question then becomes which of 
the AP-1 dimers present at a given time will bind to the TRE sites in the DNA. Could it be a
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competitive relationship based on the relative concentration of the different dimers, or is it based 
on the affinities of the dimers for the TRE site? Alternatively it could be a temporal kind of 
relationship, whereby different dimers bind sequentially, or there could be unique targets for the 
different dimers. In addition, depending on the composition of the AP-1 dimer that binds to a 
target promoter, the resultant effect could be either the activation or inhibition of gene expression. 
The possibility of multiple combinations of AP-1 dimerization partners increases the potential for 
AP-1 binding to various DNA promoter sites and allows fine-tuning of gene expression in 
response to various stimuli.
The Jun and Fos family proteins are found in many different cell types (29). These 
proteins function in the regulation of cell proliferation, transformation, differentiation and apoptosis 
(26, 27, 29). About ten years ago, another bZip protein, BATF, was identified (45). However the 
specific function of BATF in cell regulation is still not totally clear. BATF was first isolated from a 
cDNA library prepared from Epstein Barr virus (EBV)-infected human B cells (30). The highest 
levels of BATF expression were experimentally detected in an EBV-positive human B-cell line 
known as Raji, which is a cell line derived from Burkitt’s lymphoma. EBV-negative human B cells 
did not express BATF until infected with biologically active EBV. Studies by Taparowsky et al., 
demonstrated that within 24 hours of infecting human B cells with EBV, BATF mRNA was 
induced 25-fold. This suggests that the induction of BATF mRNA and protein is an early cellular 
response to the virus. Up-regulation of the expression of BATF in cells infected with EBV 
suggests that this virus may have an effect on cellular gene expression patterns through the 
increase in BATF (30, 32). BATF maintains the latency of the virus and the longevity of the 
infected cell.
Studies by Senga et al., using Ml mouse myeloid leukemia cells, showed that BATF is 
up-regulated as an early response to IL-6 or LIF stimulation. Following the stimulation, STAT3 is 
activated by phosphorylation and an increase in BATF is subsequently detected. Cell growth was 
arrested in the M l cells and these cells differentiated into macrophages as a result of the 
stimulation. These results suggest that the STAT3 pathway may modulate AP-1 activity by the 
induction of BATF in M l cells (34).
2 0
Analysis of a variety of human tissues and cell lines revealed almost exclusive 
expression of BATF mRNA in tissues of hematopoietic origin. The highest tissue expression was 
in the lungs (31,32). Considering that BATF is primarily expressed in cells of the hematopoietic 
system, we can deduce that the expression in lung tissue is most likely from alveolar 
macrophages, although this has not been directly demonstrated. BATF has been shown to be 
constitutively expressed in T lymphocytes and inducible expression was demonstrated in B 
lymphocytes.
Echlin et al. demonstrated that Jun/Fos dimers activated transcription from the 3xTRE- 
Lux reporter gene (AP-1 reporter gene) whereas BATF/Jun dimers inhibited activity of the same 
gene. Other experiments in fibroblasts also demonstrated that in the presence of the growth 
promoting effects of H-Ras or v-Fos oncoproteins, BATF reduced the cellular growth rate when 
compared to controls (26).These studies indicated that BATF may function as a negative 
regulator of AP-1. This led to our interest in the role of BATF in the function of macrophages as 
key coordinators of innate immunity. We thought it would be significant to explore the expression 
of BATF after stimulation of M l cells with inflammatory stimuli. Could BATF function to inhibit the 
inflammatory response and thus be important in down regulating adverse inflammatory 
conditions?
It has been shown that both Fos family members and BATF are able to form dimers with 
members of the Jun transcription factor family and that once these dimers have been formed, 
they have the same binding affinity for the AP-1 promoter sites in the DNA (31). Our study is 
therefore the first step to check the timeline of when Fos family members or BATF are available 
to bind to Jun. Depending on the composition of the majority of the dimers that binds to a target 
promoter, the resultant effect could be either the activation or inhibition of gene expression.
We used M l cells for continuity with previous experiments demonstrating the induction of 
BATF in response to IL-6/LIF stimulation of these cells. Although M l cells do not express c-Fos
(50), they do express Fra-1, which is also a member of the Fos family. Fra-1 dimerizes with Jun 
and the Fra/Jun dimer binding specificity to the TRE site is the same as that of the Fos/Jun dimer. 
Fra-1 has been shown to exhibit functional equivalence to Fos in the induction of differentiation
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(51). We therefore analyzed BATF expression in comparison to Fra-1 expression when M l ceiis 
were stimulated with known inflammatory triggers to determine whether either of these 
transcription factors were dominantly expressed to regulate gene expression through the target 
promoter.
2 2
CHAPTER 2.2 
MATERIALS AND METHODS
CELL CULTURE
The M1 mouse myeloid leukemia cell line was used as a monocyte/macrophage model 
(American Type Culture Collection, Manassas, VA, USA). Cells were maintained in RPMI 1640 
(Roswell Park Memorial Institute) medium with 10% (v/v) heat-inactivated fetal bovine serum, and 
50pg/ml gentamycin. The cells were Incubated in a humidified, 5% carbon dioxide incubator at 
37°C.
CELL STIMULATION
Cells were stimulated at 37°C with IL-10 or IL-6 from R&D Systems (Minneapolis, MN). The cell 
stimulation was conducted in 1ml cultures at a concentration of 5x10® cells/ml. The indicated 
mediators (i.e. LPS at lOpg/ml, IL-6 at SOng/ml and IL-10 at lOng/ml) were added at the time 
points indicated. Following the stimulation, the cells were harvested and prepared for assays to 
detect the presence of Fos, BATF, STATS and pSTATS.
SAMPLE PREPARATION
After stimulation, each sample was transferred to a microfuge tube and centrifuged to pellet the 
cells (1200 rpm, 5 minutes). The cells were washed once in serum-free RPMI 1640 and then 
lysed by addition of RIPA buffer (with 1 pg/ml each of aprotinin and leupeptin) for 15 minutes on 
ice. Samples were then centrifuged (10,000 rpm, 5 minutes, 4°C) to remove the insoluble debris. 
The supernatant, representing the cell lysate, was collected and transferred to a new tube. An 
equal volume of sample buffer containing 2-mercaptoethanol was added and the samples were 
heated for 10 minutes at 95°C to reduce and denature the proteins.
GEL ELECTROPHORESIS AND PROTEIN TRANSFER
A 10% SDS-PAGE gel was used to separate the sample proteins by size. The proteins were 
then transferred to a polyvinylidene diflouride (PVDF) membrane for detection of BATF, Fos, 
STATS and pSTATS by Western blot.
The transfer buffer used consisted of 25mM Tris, 192mM glycine and 20% (vol/vol) methanol.
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WESTERN BLOT
The PVDF membrane was incubated with a blocking buffer consisting of 5% powdered 
milk in Tris buffered saline (0.05M Tris and 0.85% NaCI), pH 7.4 with 0.05%Tween, (TBST) for 30 
minutes.
BATF detection:
BATF antiserum (kindly provided by E.J. Taparowsky, Purdue University, 1:1000 dilution) was 
added in the presence of blocking buffer for the detection of BATF and allowed to incubate, with 
rocking, for 2 hours at room temperature. The membrane was then washed with TBST for 30 
minutes, changing the buffer every 5 minutes. After the last wash, the membrane was incubated 
for one hour with the detection antibody conjugate, goat anti-rabbit IgG-HRP (1:10000 dilution in 
5% miik-TBST). The membrane was washed as before and then ECL reagent (Pierce, USA) was 
added to the membrane according to the manufacturer’s instructions. The membrane, wrapped in 
Saran Wrap, was exposed to film overnight.
Fra-1 detection:
The detection of Fra-1 followed a similar procedure to BATF except that the Fos antibody was 
directly conjugated to HRP for detection. This antibody detects c-Fos, FosB, Fra-1 and Fra-2, 
which are ail Fos family members. Fos antibody, (K-25, 1:1000 dilution, Santa Cruz 
Biotechnology, USA) was added to the blocked membrane for 2 hours, washed, then reacted with 
ECL reagent and exposed to film overnight.
STAT3 detection:
For detection of STAT3, the PVDF membrane was incubated with blocking buffer (5% powdered 
milk in TBST) for 30 minutes. STAT3 antibody (F-2,1:500 dilution, Santa Cruz) was then added 
and allowed to incubate for 2 hours. The membrane was then washed with TBST for 30 minutes, 
changing the buffer every 5 minutes. After the last wash, the membrane was incubated for one 
hour with the detection antibody conjugate, goat anti-mouse IgG-HRP (1:10000 dilution in 5% 
miik-TBST). The membrane was washed and developed as described above.
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pSTATS detection:
The detection of pSTATS followed a similar procedure except that the pSTATS mouse antibody 
(B-7) was used (1:500 dilution Santa Cruz Biotechnology, USA).
25
CHAPTER 2.3 
RESULTS
See table 3 for results showing the expression of Fra-1, BATF, STATS AND pSTATS after 
stimulation with LPS, IL-6 and IL-10.
Results showed that Fra-1 was constitutively expressed by the M l cells and, after 
stimulation with LPS, there was an increase in Fra-1 at four hours of stimulation (Fig 7A). BATF 
was also constitutively expressed but remained constant throughout the four hours of stimulation 
(Fig 7B).
Considering that LPS has been shown to lead to the direct production of IL-6, it was 
important to determine whether these effects in Fra-1 and BATF were due directly from LPS 
acting on the M l cells or indirectly from LPS inducing IL-6 production which in turn acted on the 
M l cells. IL-6 is produced by macrophages, monocytes, fibroblasts, and endothelial cells (1, 5,10) 
and has been shown to induce the terminal differentiation of M l myeloid leukemia cells to 
macrophages (52). We decided to look at IL-6 directly because it is known to activate STATS, a 
transcription factor known to induce BATF expression.
The level of expression of STATS and pSTATS was examined during the same time 
frames that as those for the detection of the expression of BATF and Fos since both IL-6 and IL- 
10 signal through the STATS pathway. Detection of pSTATS, which is the phosphorylated form of 
STATS, would give an indication of the time frame in which STATS is activated and would verify 
successful stimulation through the cytokine receptors.
After stimulation of M l cells directly with IL6, results showed that pSTATS expression 
was constant throughout the four hours of stimulation (Fig 8C) and total STATS expression 
increased (Fig 8D). Fra-1 was constitutively expressed by the Ml cells and increased over time 
after stimulation (Fig 8A). BATF was also constitutively expressed and there was a slight 
decrease in BATF following stimulation (Fig 8B).
IL-10 provides a major anti-inflammatory signal which down regulates the effects of the 
inflammatory cytokines. Results from the western blots after the four hour stimulation with IL10 
showed that there was no pSTATS detected (Fig 9C). This outcome was not expected because
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the lack of pSTATS means that the STATS pathway was not activated. Contrary to the results 
obtained after IL-6 stimulation, which showed constitutive expression of pSTATS, IL-10 showed 
no constitutive expression. However it was interesting to note that Fra-1 expression decreased 
(Fig 9A) BATF expression increased (Fig 98) and STATS expression increased (Fig 9D) even 
though we had no pSTATS expression.
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CHAPTER 2.4 
DISCUSSION
The ability to respond to extracellular signals such as cytokines is an important and integral part 
of the immune response. These extracellular signals result in the modulation of transcription 
factor activity via signal transduction pathways (6, 10). The transcription factor AP-1 consists of 
homodimers and heterodimers of bZip proteins such as Fos, Jun, ATF and BATF, which are 
capable of binding onto the TRE site of various promoters to activate the associated gene 
transcription (24). Regulation of gene expression is not mediated solely by a particular set of 
transcription factors but rather may involve many combinations of transcription factors. We 
determined the level of expression of BATF in comparison to Fos expression when Ml cells were 
stimulated with the inflammatory mediators IL-6, LPS and IL-10. The promoters of many 
inflammatory cytokine genes contain AP-1 binding sites (54), suggesting a role for AP-1 during 
inflammation.
Fos/Jun dimer complexes also function in gene regulation of a number of functions in 
the cell such as cell growth and development (27, 28, 29, 31, 53). The BATF/Jun dimer has been 
shown to negatively regulate/inhibit functions in the cell (26, 30, 31, 33). However the function of 
BATF during inflammation remains largely unclear. We therefore analyzed the level of BATF 
expression in comparison to Fos expression because both these bZip proteins are capable of 
dimerizing with Jun. Once these dimers are formed, only then can the binding to the TRE DNA 
binding site occur and thus gene regulation can occur (11, 24, 26, 27, 53). It has been shown that 
Fos/Jun dimers have the same affinity of binding to the TRE site as BATF/Jun dimers (26,31). 
Therefore from the experiments we performed and the above information, it would be reasonable 
to assume that the concentration of Fos in relation to BATF is a major determinant as to which of 
the two dimers will bind to the TRE site and thus regulate expression of the associated gene. It 
was observed that throughout the 4 hour periods, neither BATF nor Fos disappeared completely 
but were instead coexpressed. However one of the two bZip proteins was upregulated and the 
other downregulated or remained constant (Fig 7A, 7B, BA, 8B, 9A, 9B). Therefore the balance 
between Fos and BATF determined what kind of response persisted. If BATF indeed acts as a
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negative regulator of inflammation, the results would be consistent with research done by P. 
Ward (55) where he inferred that pro-inflammatory and anti-inflammatory mediators are 
generated at the same time. The balance between these two classes of mediators determines 
whether the inflammatory response persists and intensifies or whether it is contained. In other 
words, both types of mediators could be expressed at the same time. However, the relative level 
of expression of each mediator is what determines the type of response.
From the results shown, BATF expression remained constant when M1 cells were 
stimulated with LPS (Fig. 78), whereas Fra-1 expression (Fig. 7A) increased. This suggests that 
with regards to Fos and BATF, Fos is the more dominant transcription factor in response to LPS. 
The most likely explanation of the results would be that LPS induced the MAP kinase pathway 
and it also induced the activation of the NFkB pathway (Fig. 5). TPA uses the MAP kinase 
pathway to upregulate both Fos and Jun (56). Considering that LPS activates the same pathway 
as TPA, we would expect that LPS also increases Fos expression via the MAP kinase pathway. 
The MAPK pathway also results in the activation of JUN kinase which in turn phosphorylates Jun. 
The phosphorylation of Jun has been linked with induction of transcriptional activity.
NFkB has been shown to physically interact with Fos/Jun, lending synergy to the 
induction of the inflammatory response. Experiments by Lui et al. (57) showed that BATF is 
induced following direct NFkB activation. From our results we observed that BATF was present 
even though Fos was the dominant of the two transcription factors. The presence of BATF 
probably helps limit the extent to which inflammation is occurring. These results fit our proposed 
model for a hypothetical inflammatory response dependent on Fos and BATF.
When Ml cells were stimulated with IL-6, there was an increase in Fra-1 expression (Fig. 
8A) and there was a decrease in BATF following stimulation (Fig. 8B). Contrary to the results by 
Senga et al. (34), in which BATF expression was induced following stimulation with IL-6, our 
results show that we had constitutive expression of BATF. This discrepancy in results may be due 
to different cell culture conditions. We used cells that had adhered to the flask during culture and 
it is possible that these monocytes could have already differentiated into macrophages during 
routine culture. Macrophages are capable of making IL-6 during culture, in turn the presence of
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IL-6 leads to cell differentiation of the myeloid leukemic cell line, M1, to macrophages (50, 52). 
The constitutive expression of BATF could therefore be due to the fact that the stimulation was 
actually done on a mixed cell population of monocytes and macrophages rather than solely on 
monocytes.
The fact that following IL-6 stimulation, Fra-1 expression increased whereas BATF 
expression decreased, suggests that with regards to Fos and BATF, Fos is the more dominant 
transcription factor in response to IL-6. IL-6 is known to activate the MAPK pathway via the SHP2 
domain (Fig 4) (58). This would in turn give rise to an increase in Fos expression. Our results also 
show that the STATS pathway was activated due to the presence of pSTATS whose expression 
remained constant whereas the total STATS expression increased. Increase in total STATS 
expression is most likely an indication of the continued activation of the pathway.
Following stimulation of the M l cells with the key anti-inflammatory cytokine, IL-10, there 
was a decrease in Fra-1 expression (Fig 9A) and an increase in BATF expression (Fig 9B). 
However one unexpected outcome of the experiments was that there was no expression of 
pSTATS (Fig 9C) as a result of the stimulation. The lack of pSTATS indicates that the STATS 
pathway was not activated following stimulation of the M l cells with IL-10. One likely reason for 
the discrepancy would be that the M l cell line may lack IL-10 receptors Most monocyte cell lines 
do have IL-10 receptors; however their presence on Ml cells is unknown. Another possible 
explanation could be that the STATS pathway may be inhibited at some point in the signaling 
pathway. This would have most likely involved inhibition of phosphorylation of STATS by blocking 
signaling upstream of this event (see fig 5). For example, inhibition of tyrosine kinase (Tyk) could 
lead to inhibition of STATS activation.
Looking at our proposed model (fig 6) and the results we obtained, we could conclude the 
results from our experiments loosely fit the model. This model is naïve in comparison to the 
complexity of the transcriptional regulation of the inflammatory response during inflammation. 
There are many variables with respect to the possibility of signaling pathway crosstalk as well as 
gene regulation.
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Following all the experiments to determine the role of BATF in the inflammatory 
response, we realized that changes need to be made in some aspects of the experiments. One 
important change would be the use of a cell line whose exact stage of differentiation is known. 
During our experiments, the cell line was probably a mixed cell population in terms of the various 
stages of differentiation. Over time, some cells began to adhere to the cell culture flask while 
others remained nonadherant and we used both for the experiments. Some cells were most likely 
mature macrophages (those adhering to the flask), whereas other cells were just newly divided 
Ml cells. It would be helpful to stain the cells with antibodies to monocyte or macrophage 
differentiation markers to determine the differentiation state of the cell population. Knowing the 
specific receptors expressed would clarify the probable pathways that could be activated and thus 
shed some light on interactions that are likely occurring.
In addition, use of inhibitors to specific pathways would help sort out which pathways are 
being activated in response to a specific stimulus. For example, to find out if LPS is activating the 
MARK pathway directly or indirectly through the induction of IL-6, an SHP2 inhibitor could be 
used to block the pathway used by IL-6. If the MAPK pathway is still activated, one can then infer 
that LPS is directly activating that pathway. We could also check to see if IL-6 is being made in 
culture by measuring IL-6 in the media following routine culture. This would give us insight as to 
whether IL-6 could have caused differentiation of the monocytes into macrophages. The use of 
primary macrophages or monocytes could help reflect what actually goes on physiologically in 
vivo as opposed to using M1 cells which are a myeloid leukemia cell line. These M1 cells lack c- 
Fos but have Fra-1 whereas primary cells express c-Fos. There is also a possibility that the IL-10 
receptors were hyporesponsive In the myeloid leukemia cells. In neutrophils, it has been shown 
that their capacity to respond to IL-10 is dependent on the level of expression of the IL-10 
receptor (59,60).
Once the time course of transcription factor expression is fully described, a second stage 
of the research would be to measure transcription factor binding to an AP-1 consensus DNA 
sequence. This would give more conclusive evidence as to which of the two dimers (BATF/Jun 
or Fos/Jun) is actually binding and thus giving rise to the control of the TRE site foilowing the
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stimulations. This could be done by use of the electrophoretic mobility shift assays (EMSA). To 
investigate the DNA binding preference of BATF/Jun compared to Fos/Jun complexes, to the 
TRE SITE, radiolabeled AP-1 (TRE) oligonucleotides would be used. Following the stimulations, 
nuclear extracts could be used to generate protein/DNA complexes that can then be resolved by 
electrophoresis through polyacrylamide gels and visualized by autoradiography.
This would give more conclusive data as to whether BATF/Jun or Fos/Jun dimers 
actually compete for the same binding site or have different target sites altogether. In summation, 
the groundwork to finding the transcriptional regulation of the macrophage response in 
inflammation has been initiated.
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TABLES
CYTOKINE FUNCTION
Macrophage Migration Inhibitory Factor (MIF) Activates macrophages and inhibits their 
migration
Macrophage Activating Factor (MAF), Affects activation, growth and differentiation of 
macrophages
Leukemia Inhibitory Factor (LIF) Promotes differentiation of monocytes to 
macrophages
Macrophage Fusion Factor (MFF), Induces the fusion of bone marrow cells and 
alveolar macrophages to large multinucleated 
cells that produce high levels of IL-1.
Interleukin 2 (IL-2) Stimulates cell growth and development
Interleukin 3 (IL-3) Growth factor for hematopoietic cells stimulates 
colony formation
Interleukin 4 (IL-4) Promotes cell growth and development
Interleukin 6 (IL-6) Pro-Inflammatory
Interleukin 10 (IL-10) Anti-inflammatory
Interleukin 13 (IL-13) Suppresses inflammatory responses
Interleukin 16 (IL-16) Stimulates migration of cells
Interleukin 17 (IL-17) Enhances expression of ICAM-1, thus making 
cells more adhesive
Tumor Necrosis Factor alpha (TNF-a) Strong mediator of inflammatory and immune 
functions
Tumor Necrosis Factor beta (TNF-3) Regulates cell growth and differentiation
Interferon gamma (IFN- y) Affects activation, growth and differentiation of 
cells. Upregulates MHC expression on antigen 
presenting cells.
Granulocyte-Macrophage Colony Stimulating 
Factor (GM-CSF)
Differentiation factor for granulocytic and 
monocytic cell lineages.
Monocyte Colony Stimulating Factor (M-CSF) Essential for growth and differentiation of 
monocytes.
Colony Stimulating Factor 1 (CSF-1) Essential for cell growth and differentiation
Table 1: Cytokines for which macrophages have receptors and the functions of the 
cytokines (1, 5, 10)
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Enzymes -Lysozyme
-Lysosomal acid hydrolases
• Lipases
• Proteases
• (Deoxy)ribonuclease
• Phosphatases
• Glycosidases
• Sulfatases
Complement Components -Classical pathway
• C1,C4,C2,C3,C5 
-Alternative pathway 
factor B, factor D, properdin
Reactive Oxygen Intermediates -Superoxide 
-Hydrogen peroxide 
-Hydroxyl radical 
-Nitric oxide 
-Peroxynitrite
Cytokines -IL-1,IL-6,IL-10.IL-12, IL-15, IL-18 
-TNF-a
-Interferons-a and y 
-Platelet-derived growth factors 
-Fibroblast growth factor 
-Transforming growth factor-(3 
-GM-CSF 
-Erythropoietin
-Factor inducing monocytopoiesis 
-Angiogenesis factor
-CXC chemokines (IL-8, GRO, ENA-78, IL-10)
Table 2. Macrophage Secretory Products (1, 5,10)
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LPS IL-6 IL-10
Fra-1 Increased Increased Decreased
BATF Constant Decreased Increased
STAT3 Not Done Increased Increased
pSTAT3 Not Done Constant No results
Table 3: Results showing the expression of Fra-1, BATF, STATS AND pSTAT3 after 
stimulation with LPS, IL-6 and IL-10.
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FIGURES
Figure 1: The structure o f the classical AP-1/DNA complex. AP-1 is a dimer formed by Jun 
and its non-homologous protein Fos. It contains a ieucine zipper motif where two alpha heiices 
look like a zipper with leucine residues iining up on the inside of the zipper. The leucine-zipper- 
containing transcription factor binds DNA as a dimer (25)
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Jun Fos
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Figure 2: Proposed relationship between Fos/Jun (AP-1) and BATF/Jun in gene 
regulation in the macrophage.
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Figure 3: TLR4 Pathway (38, 40, 41)
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Figure 4: IL-6 Pathway (44, 45, 46)
IL-10R1 cytokine
^ L ^ ^ c y to k in e  receptor
IL-10R2_— — =^r|j — ceil membrane
■ TYK ' 'JAK1
STAT3 P-STAT3
PSTAT3 (Dimer)
m lO R
MAPK
transcription
Figure 5: IL 10 pathway (46, 48, 49)
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Time
Figure 6: Simple model to demonstrate proposed timeline of expression of Fos relative to 
BATF during an inflammatory response. Grey indicates Fos/Jun activity; gene transcription is 
promoted resulting in an inflammatory response. White indicates BATF/Jun activity; gene 
transcription is suppressed resulting in the resolution of inflammation.
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Figure 7: Stimulation ofM1 ceils with LPS. M1 cells were stimulated with LPS (10pg/ml) for 
0-4 hours and harvested. Whole cell lysates were used for the detection o f Fra-1 (A), BATF (B).
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Figure 8: Stimulation ofM1 cells with IL-6. M1 cells were stimulated with IL6 (50ng/ml) for 0-4 
hours and harvested. Whole cell lysates were used for the detection o f Fra-1 (A), BATF (B), 
STAT3 (C) and pSTAT3 (D) by Western blot. All experiments were repeated on different days to 
ensure reproducibility of results.
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Figure 9: Stimulation of M l cells IL-10. M1 cells were stimulated with IL10 (lOng/ml) for 0-4 
hours and harvested. Whole cell lysates were used for the detection o f Fra-1 (A), BATF (B), 
STAT3 (C) and pSTAT3 (not shown) by Western blot. All experiments were repeated on different 
days to ensure reproducibility of results.
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